Webinar recording:ALS Caregiving, Technology, and Trial Inclusion
Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive neurological disorder characterized by degeneration of motor neurons, leading to debilitating muscle weakness and speech difficulties.
Early, precise, and continuous monitoring of ALS symptoms is crucial for effective patient care and the development of new drugs.
Modality.AI's AI-driven speech and visual analytics objectively assess ALS progression, enabling clinicians, researchers, and pharmaceutical companies to access accurate, real-time data. Our platform offers sensitive and scalable measures to enhance clinical trial efficiency, improve patient engagement, and enhance the quality of life.
. . .
Peer-reviewed publications demonstrate Modality.AI’s commitment to advancing ALS research.
These publications provide insights into speech, facial, and motor biomarkers, showcasing how our multimodal analytics platform enhances clinical trials and deepens scientific understanding of ALS progression. Our collaborations with leading institutions and biopharma partners underscore the rigor and impact of our technology, reflecting our dedication to improving outcomes for patients and caregivers alike.
Featured publications:
Many additional publications can be found at: https://modality.ai/publications/als
Conducting a clinical trial or research study in ALS and want to learn more?
Click here to schedule a demonstration.
We're pleased to share lessons learned from clinical trials, and highlight emerging trends in ALS assessment and management through discussions, conference talks, and interactive sessions led by our team and our collaborators from research institutions and biopharma.
. . .
Modality.AI is proud to collaborate with leading academic institutions, biotech and pharmaceutical companies, and patient advocacy groups dedicated to advancing ALS research and patient care. Our partnerships leverage combined expertise, resources, and shared visions to drive breakthroughs in understanding disease progression, accelerating drug development, and enhancing patient outcomes.
. . .
Conducting a clinical trial or research study in ALS and want to learn more?
Click here to schedule a demonstration.
Follow our progress as we continue to innovate, collaborate, and deliver meaningful contributions to the ALS community.
Kely Norel: Assessment of speech intelligibility for remote tracking of ALS progression
Modality Research Scientist Michael Neumann, PhD Presents at ENCALS
Announcing Results from Verge Genomics Proof-of-Concept ALS Clinical Trial
Target ALS Webinar with Amy Easton, Senior Director of Scientific Programs
Modality to Present at 35th International Symposium on ALS/MND
Target ALS and Modality.AI Collaborate in Multimodal Study of ALS
. . .